1991 Volume 39 Issue 11 Pages 1071-1085
We evaluated the clinical efficacy of intramuscular imipenem/cilastatin sodium (IPM/CS) in the treatment of urinary tract infections and measured the in vitro antibacterial activity of imipenem (IPM).
1. The antibacterial activity of IPM against clinical isolates from patients with complicated urinary tract infections was compared with that of control drugs: piperacillin (PIPC), cefmetazole (CMZ), ceftazidime (CAZ), gentamicin (GM) and ofloxacin (OFLX).The antimicrobial activity of IPM was similar to that of CAZ against Escherichia coli and was higher than that of PIPC, CMZ, CAZ, GM and OFLX against organisms other than Escherichia coli.
2. Thirty three patients with complicated urinary tract infections were treated with intramuscular IPM/CS250mg/250mg or500mg/500mg bid.for5days. According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 76%. No adverse reactions were observed in the33patients.Elevation of GOT and GPT was noted in2patients and a decrease in neutrophils and an increase in lymphocytes was noted in one patient.
We conclude that intramuscular IPM/CS is effective and safe in the treatment of complicated urinary tract infections.
